Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBIT Margin: 2010-2024

Historic EBIT Margin for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -101.32%.

  • China Pharma Holdings' EBIT Margin rose 1558.00% to -83.06% in Q3 2025 from the same period last year, while for Sep 2025 it was -79.83%, marking a year-over-year increase of 272.00%. This contributed to the annual value of -101.32% for FY2024, which is 6208.00% down from last year.
  • According to the latest figures from FY2024, China Pharma Holdings' EBIT Margin is -101.32%, which was down 158.16% from -39.25% recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' EBIT Margin ranged from a high of -23.73% in FY2020 and a low of -101.32% during FY2024.
  • Its 3-year average for EBIT Margin is -61.45%, with a median of -43.79% in 2022.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 16,309bps in 2020, then crashed by 6,208bps in 2024.
  • Yearly analysis of 5 years shows China Pharma Holdings' EBIT Margin stood at -23.73% in 2020, then tumbled by 594bps to -29.67% in 2021, then plummeted by 1,412bps to -43.79% in 2022, then spiked by 454bps to -39.25% in 2023, then slumped by 6,208bps to -101.32% in 2024.